{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant PD, and disease-associated mutations disrupt its function in phosphorylating Akt1, a key cell survival molecule.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links LRRK2 mutations to impaired Akt1 phosphorylation, a critical pathway for neurodegeneration in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used in vitro kinase assays and knockdown experiments to assess LRRK2 phosphorylation of Akt1 (Ser473), a well-established functional readout for LRRK2 activity.",
          "judgment": "Yes",
          "reasoning": "Kinase assays and knockdown experiments are standard methods to evaluate protein phosphorylation and functional interactions in LRRK2 research.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study used recombinant proteins and intact cells but did not explicitly describe controls (wild-type vs. mutant) or replicate counts in the provided text.",
          "judgment": "No",
          "reasoning": "The absence of explicit details on controls and replicates prevents confirmation of basic validation criteria in Sub-step 3a.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The assays (kinase assays and pull-down experiments) are standard techniques in LRRK2 research and were previously validated for Akt1 phosphorylation.",
          "judgment": "Yes",
          "reasoning": "The methods align with broadly accepted assays in the field, even without explicit controls/replicates mentioned in the text.",
          "next_step_or_outcome": "Functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1441C variant shows reduced Akt1 phosphorylation in LRRK2 functional assays. While the assays are valid and relevant to PD pathogenesis, the lack of explicit controls/replicates limits strength to 'supporting' (PS3_supporting)."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations (e.g., G2019S) disrupt Akt1 phosphorylation, a critical pathway for neurodegeneration in PD.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links G2019S to impaired Akt1 phosphorylation, a core mechanism of LRRK2-related PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used in vitro kinase assays and knockdown experiments to assess Akt1 phosphorylation, standard methods in LRRK2 functional analysis.",
          "judgment": "Yes",
          "reasoning": "Kinase assays and knockdown experiments are well-established for evaluating LRRK2 activity and functional disruptions.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study used recombinant proteins and intact cells but did not explicitly describe controls or replicates in the provided text.",
          "judgment": "No",
          "reasoning": "The absence of explicit controls/replicates prevents validation under Sub-step 3a.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The assays (kinase assays and pull-down experiments) are standard techniques in LRRK2 research and were previously validated for Akt1 phosphorylation.",
          "judgment": "Yes",
          "reasoning": "The methods align with broadly accepted assays in the field, even without explicit controls/replicates mentioned in the text.",
          "next_step_or_outcome": "Functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S variant shows reduced Akt1 phosphorylation in LRRK2 functional assays. While the assays are valid and relevant to PD pathogenesis, the lack of explicit controls/replicates limits strength to 'supporting' (PS3_supporting)."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations (e.g., I2020T) disrupt Akt1 phosphorylation, a critical pathway for neurodegeneration in PD.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links I2020T to impaired Akt1 phosphorylation, a core mechanism of LRRK2-related PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used in vitro kinase assays and knockdown experiments to assess Akt1 phosphorylation, standard methods in LRRK2 functional analysis.",
          "judgment": "Yes",
          "reasoning": "Kinase assays and knockdown experiments are well-established for evaluating LRRK2 activity and functional disruptions.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study used recombinant proteins and intact cells but did not explicitly describe controls or replicates in the provided text.",
          "judgment": "No",
          "reasoning": "The absence of explicit controls/replicates prevents validation under Sub-step 3a.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The assays (kinase assays and pull-down experiments) are standard techniques in LRRK2 research and were previously validated for Akt1 phosphorylation.",
          "judgment": "Yes",
          "reasoning": "The methods align with broadly accepted assays in the field, even without explicit controls/replicates mentioned in the text.",
          "next_step_or_outcome": "Functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The I2020T variant shows reduced Akt1 phosphorylation in LRRK2 functional assays. While the assays are valid and relevant to PD pathogenesis, the lack of explicit controls/replicates limits strength to 'supporting' (PS3_supporting)."
    }
  ]
}